KROS
Keros Therapeutics, Inc. (KROS) Management Analysis (2026)
Overall Score
Capital Allocation
Management is preserving a very strong liquidity position, with current ratio at 21.96x and cash per share at 13.01.
Balance sheet leverage remains low, with debt-to-equity at 0.06x and debt-to-assets at 0.05x.
However, capital efficiency remains weak given negative free cash flow and negative return on invested capital.
Execution Operating Discipline
Management is operating with high gross margin of 94.7%, but profitability remains deeply negative at the operating and net levels.
Working capital management is mixed, with a very long payables cycle offsetting a 67-day receivables cycle.
The company continues to show weak cash generation, with operating cash flow and free cash flow both negative.
Incentives Governance
Stock-based compensation remains meaningful at 1.52% of revenue, which can dilute shareholder returns if not offset by growth.
No material governance or incentive changes were identified this month.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Keros Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

